81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery

Checkmate 816 has established a new standard of care for operable NSCLC, combining neoadjuvant nivolumab with 3 cycles of platinum-based chemotherapy, granted approval in the UK in March 2023. This represents a shift in practice from traditional adjuvant treatment, with implications for patient care and service delivery.

Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Taher Abu, Alexius John, Faisal Rehman, Charlotte Milner-Watts, David McMahon, Thubeena Manickavasagar, Elizabeth Cartwright, Nadia Yousaf, Domingo Vicente Cano Gil, Carol Tan, Jeremy Smelt, Ian Hunt, Simon Jordan, Sofina Begum, Jaishree Bhosle, Anna Minc Tags: NSCLC Systemic Treatment Source Type: research